Skip to content

King Pharmaceuticals KG Workers' Compensation — Year 9

Other product segments

European Hospital Liability
4.9%
General Liability
3.8%
Commercial Auto Liability
1.6%
International
-0.7%
All other lines
-0.4%

Similar metrics at other companies

Old Republic International logo
ORIWorkers' Compensation — Year 9
1.5%+0.5pp
CNA Financial logo
CNAWorkers' Compensation — Year 9
0.8%-0.2pp
United Fire Group logo
UFCSCommercial workers' compensation — Year 9
0.1%-0.7pp
The Hartford Financial Services Group logo
HIGWorkers' Compensation — 9th Year
1.5%-0.2pp
Old Republic International logo
ORIWorkers' Compensation — Year 10
3.3%+2.8pp
CNA Financial logo
CNAWorkers' Compensation — Year 8
1.2%0.0pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearNine.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's workers' compensation — year 9.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's workers' compensation — year 9?
King Pharmaceuticals (KG) reported workers' compensation — year 9 of 1.2% in Q4 2025.
What does workers' compensation — year 9 mean?
This metric represents the financial performance of the Workers' Compensation insurance segment during the ninth year. It is essential for analyzing year-over-year trends in premium volume and segment-specific profitability.